Impact of cabozantinib on plasma adrenocorticotropic hormone and serum cortisol concentrations in individuals with metastatic renal cell carcinoma: a retrospective analysis - Top-Institutions - MDSpire

Impact of cabozantinib on plasma adrenocorticotropic hormone and serum cortisol concentrations in individuals with metastatic renal cell carcinoma: a retrospective analysis

  • By

  • Yuji Hataya

  • Mayuka Kurata

  • Kimiaki Murabe

  • Takuro Hakata

  • Kanta Fujimoto

  • Toshio Iwakura

  • Toshinari Yamasaki

  • Naoki Matsuoka

  • November 4, 2025

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Medical Oncology
    • Endocrinology
    • Pharmacology

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Medical Oncology
    • Endocrinology

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Medical Oncology
    • Endocrinology
    • Clinical Pharmacology

  • #4

    National Cancer Center Hospital
    National Cancer Center Hospital

    Tokyo, Japan

    Key Differentiators

    • Medical Oncology
    • Endocrinology

  • #5

    Kobe City Medical Center General Hospital
    Kobe City Medical Center General Hospital

    Kobe, Japan

    Key Differentiators

    • Medical Oncology
    • Endocrinology

Original Source(s)

Impact of cabozantinib on plasma adrenocorticotropic hormone and serum cortisol concentrations in individuals with metastatic renal cell carcinoma: a retrospective analysis

  • by Yuji Hataya, Mayuka Kurata, Kimiaki Murabe, Takuro Hakata, Kanta Fujimoto, Toshio Iwakura, Toshinari Yamasaki, Naoki Matsuoka

  • November 4, 2025

Related Content

Synthetic short RNA in cancer

Beyond inhibition: harnessing the DRD2–VEGF-A feedback loop for precision anti-angiogenesis therapy in cancer

Myelodysplastic syndromes complicated by atypical Sweet syndrome: a brief research report